← Back to Search

Insulin Delivery System

Insulin-Glucose Infusion System for High Blood Sugar

Phase 1 & 2
Waitlist Available
Led By Timothy W Valk, MD
Research Sponsored by Admetsys Corporation
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Type 1 or type 2 diabetic individuals on insulin ages 21-85 with A1c 7-9.9%
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up data will be evaluated within 6 months after completion of all 40 studies
Awards & highlights

Study Summary

This trial is testing a new system that regulates blood sugar levels without causing low blood sugar levels. The system will be used in intensive care units and during surgery.

Who is the study for?
This trial is for adults aged 21-85 with Type 1 or Type 2 diabetes, currently on insulin therapy, and have high blood sugar levels (>150 mg/dl) at the time of study. Their A1c levels should be between 7-9.9%. People who are pregnant, using corticosteroids, or have kidney/liver diseases, electrolyte imbalances, anemia or poor veins for drips cannot join.Check my eligibility
What is being tested?
The study tests a system that balances glucose and insulin delivered directly into the bloodstream while frequently checking blood sugar levels. The goal is to maintain stable blood sugar without causing low blood sugar in patients in intensive care units or during surgery.See study design
What are the potential side effects?
Potential side effects may include risks associated with maintaining tight control of blood sugar such as low blood sugar (hypoglycemia), especially since this involves frequent adjustments to insulin infusion based on real-time monitoring.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am 21-85 years old with diabetes on insulin and my A1c is between 7-9.9%.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~data will be evaluated within 6 months after all 40 studies are completed
This trial's timeline: 3 weeks for screening, Varies for treatment, and data will be evaluated within 6 months after all 40 studies are completed for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
glucose control in target range
Secondary outcome measures
hypoglycemia

Trial Design

1Treatment groups
Experimental Treatment
Group I: insulin and glucose infusionExperimental Treatment1 Intervention
trial of experimental technique in outpatient setting; the group under study will be comprised of type 1 and type 2 diabetic individuals ; they will have automated treatment using algorithm which regulates balancing infusions of glucose and/or insulin intravenously without manual intervention; blood glucose target of 80-180 mg/dl will be guide for the automated system

Find a Location

Who is running the clinical trial?

Admetsys CorporationLead Sponsor
Timothy W Valk, MDPrincipal InvestigatorAdmetsys Corporation

Media Library

Insulin Balanced Infusion System (Insulin Delivery System) Clinical Trial Eligibility Overview. Trial Name: NCT01291719 — Phase 1 & 2
High Blood Sugar Research Study Groups: insulin and glucose infusion
High Blood Sugar Clinical Trial 2023: Insulin Balanced Infusion System Highlights & Side Effects. Trial Name: NCT01291719 — Phase 1 & 2
Insulin Balanced Infusion System (Insulin Delivery System) 2023 Treatment Timeline for Medical Study. Trial Name: NCT01291719 — Phase 1 & 2

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
~4 spots leftby Nov 2025